TAOX logo

TAO SYNERGIES INC

TAOXNASDAQ
🏆 #4626 by market capEarnings Dec 2US Equity
$4.32▼ $0.03 (−0.69%)
🌙 After hours$4.34▲ 0.46%Regular close · extended-hours price shown
🔔
Track TAOX
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 0.7%
7d▲ 0.9%
14d▲ 17.7%
30d▲ 7.7%
ytd▲ 16.1%
1y▼ 33.7%
🏦Market Cap
$32M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
99.9%
High
💵FCF Margin
-803.0%
Thin
⚖️P/S Ratio
41.8x
Expensive
Otter Score
60
Fair

Trading Snapshot

Day Range
$4.27 – $4.34
52-Week Range
$3.07 – $10.00
Volume
$3.36B
Avg Volume
$4.44B
Shares Outstanding
7.5M
Next Earnings
Oct 29, 2026

Fundamentals Snapshot

Annual Revenue
$299,061
Last Q Revenue
$88,626
P/E Ratio
-1.1
P/S Ratio
41.8x
EPS (TTM)
$-2.23
Dividend Yield
0.00%
Dilution (1yr)
+448.8%

Why Investors Own TAOX

  • ✓High-growth profile — revenue up +27.5% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 34% gross margin and 14% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

TAOX logo

TAO SYNERGIES INC

TAOX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$299K▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$9M▲ +32.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$6M▲ +30.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
7.4M▲ +448.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$5M▼ −$12M YoY
StockOtter · stockotter.space

About TAO SYNERGIES INC

TAO Synergies Inc. operates as a biopharmaceutical company currently in the clinical development stage. It is dedicated to advancing a bryostatin-1 therapeutic platform, specifically designed to combat Alzheimer's and various other neurodegenerative and cognitive disorders. Beyond its drug development efforts, the firm is also diversifying its treasury strategy, with a new approach centered on the management of digital assets, primarily focusing on the acquisition and 'staking' of TAO cryptocurrency.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Ratings

ⓘ
Consensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Apr 2025

Latest News & Updates

Defense World·21d ago

Synaptogenix (NASDAQ:TAOX) & Shineco (NASDAQ:SISI) Head-To-Head Contrast

Synaptogenix (NASDAQ: TAOX - Get Free Report) and Shineco (NASDAQ: SISI - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of th

Benzinga·Aug 5

James Altucher Prefers AI's Picks And Shovels; Calls Quantum Computing Science Fiction

Credit: James Altucher(an investor, venture capitalist, writer, entrepreneur, co-Founder TAO Synergies) and Anna Tutova(Founder AI Crypto Minds) at Proof of Talk Summit in Paris.

PRNewsWire·Jul 8

TAO Synergies Appoints Bittensor Investor and Author Mark Jeffrey as Advisor

Early Bitcoin author, decentralized AI fund manager, and host of the Hash Rate podcast joins TAOX as the Company expands subnet investing and decentralized AI development NEW YORK, July 8, 2026 /PRNewswire/ -- TAO Synerg